Antidepressant-like effect of Cordyceps sinensis in the mouse tail suspension test. 2007

Koji Nishizawa, and Kosuke Torii, and Aya Kawasaki, and Masanori Katada, and Minoru Ito, and Kenzo Terashita, and Sadakazu Aiso, and Masaaki Matsuoka
Noevir-Keio Research Laboratory, Noevir Co., Ltd, Shinjuku-ku, Tokyo 160-8582, Japan.

Cordyceps sinensis (CS) has been known as a component of traditional medicines that elicit various biological effects such as anti-fatigue, immunomodulatory, and hypoglycemic actions. Since it has been well-established that fatigue is closely related to depression, we used the tail suspension test (TST) in mice to examine the antidepressant-like effects of hot water extract (HWCS) and supercritical fluid extract (SCCS) of CS. Immobility time in the TST was reduced by administration of SCCS (2.5-10 ml/kg, p.o.) dose-dependently though it was not reduced by treatment with HWCS (500-2000 mg/kg, p.o.). Neither HWCS nor SCCS altered locomotor activity in the open field test, excluding the possibility that the effect of SCCS is due to activation of locomotion. Pretreatment with prazosin (an adrenoreceptor antagonist) or sulpiride (a dopamine D2 receptor antagonist) reduced the effect of SCCS on the immobility time. In contrast, pretreatment with p-chlorophenylalanine (p-CPA, a serotonin synthesis inhibitor) did not alter the anti-immobility effect of SCCS. The last finding is consistent with an additional observation that SCCS had no effect on head twitch response induced by 5-hydroxy-L-tryptophan in mice. Taken altogether, these results suggest that SCCS may elicit an antidepressant-like effect by affecting the adrenergic and dopaminergic systems, but not by affecting the serotonergic system.

UI MeSH Term Description Entries
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D011224 Prazosin A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION. Furazosin,Minipress,Pratsiol,Prazosin HCL,Prazosin Hydrochloride,HCL, Prazosin,Hydrochloride, Prazosin
D003010 Clorgyline An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE. Clorgilin,Chlorgyline,Clorgiline
D003891 Desipramine A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors. Desmethylimipramine,Apo-Desipramine,Demethylimipramine,Desipramine Hydrochloride,Norpramin,Novo-Desipramine,Nu-Desipramine,PMS-Desipramine,Pertofran,Pertofrane,Pertrofran,Petylyl,Ratio-Desipramine,Apo Desipramine,Hydrochloride, Desipramine,Novo Desipramine,Nu Desipramine,PMS Desipramine,Ratio Desipramine
D005473 Fluoxetine The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants. Fluoxetin,Fluoxetine Hydrochloride,Lilly-110140,N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine,Prozac,Sarafem,Lilly 110140,Lilly110140
D006916 5-Hydroxytryptophan The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant. 5-HTP,Hydroxytryptophan,Oxitriptan,Oxytryptophan,Tryptophan, 5-Hydroxy-,5 Hydroxytryptophan,5-Hydroxy- Tryptophan,Tryptophan, 5 Hydroxy
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic

Related Publications

Koji Nishizawa, and Kosuke Torii, and Aya Kawasaki, and Masanori Katada, and Minoru Ito, and Kenzo Terashita, and Sadakazu Aiso, and Masaaki Matsuoka
November 2008, Journal of pharmacological sciences,
Koji Nishizawa, and Kosuke Torii, and Aya Kawasaki, and Masanori Katada, and Minoru Ito, and Kenzo Terashita, and Sadakazu Aiso, and Masaaki Matsuoka
December 2005, Psychopharmacology,
Koji Nishizawa, and Kosuke Torii, and Aya Kawasaki, and Masanori Katada, and Minoru Ito, and Kenzo Terashita, and Sadakazu Aiso, and Masaaki Matsuoka
January 2022, Biological & pharmaceutical bulletin,
Koji Nishizawa, and Kosuke Torii, and Aya Kawasaki, and Masanori Katada, and Minoru Ito, and Kenzo Terashita, and Sadakazu Aiso, and Masaaki Matsuoka
January 2012, Indian journal of pharmacology,
Koji Nishizawa, and Kosuke Torii, and Aya Kawasaki, and Masanori Katada, and Minoru Ito, and Kenzo Terashita, and Sadakazu Aiso, and Masaaki Matsuoka
February 2016, Progress in neuro-psychopharmacology & biological psychiatry,
Koji Nishizawa, and Kosuke Torii, and Aya Kawasaki, and Masanori Katada, and Minoru Ito, and Kenzo Terashita, and Sadakazu Aiso, and Masaaki Matsuoka
May 2014, Natural product communications,
Koji Nishizawa, and Kosuke Torii, and Aya Kawasaki, and Masanori Katada, and Minoru Ito, and Kenzo Terashita, and Sadakazu Aiso, and Masaaki Matsuoka
March 2010, Progress in neuro-psychopharmacology & biological psychiatry,
Koji Nishizawa, and Kosuke Torii, and Aya Kawasaki, and Masanori Katada, and Minoru Ito, and Kenzo Terashita, and Sadakazu Aiso, and Masaaki Matsuoka
November 2006, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Koji Nishizawa, and Kosuke Torii, and Aya Kawasaki, and Masanori Katada, and Minoru Ito, and Kenzo Terashita, and Sadakazu Aiso, and Masaaki Matsuoka
October 2012, Progress in neuro-psychopharmacology & biological psychiatry,
Koji Nishizawa, and Kosuke Torii, and Aya Kawasaki, and Masanori Katada, and Minoru Ito, and Kenzo Terashita, and Sadakazu Aiso, and Masaaki Matsuoka
March 2004, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Copied contents to your clipboard!